Matches in SemOpenAlex for { <https://semopenalex.org/work/W284128977> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W284128977 endingPage "625" @default.
- W284128977 startingPage "619" @default.
- W284128977 abstract "Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease that causes significant morbidity and mortality. RA patients should be started with DMARD represented by methotrexate (MTX) as early as possible. However, even use of MTX often fails to control disease activity and to prevent structural damage and, thereby, more effective treatment strategies are needed. Since TNF-alpha and IL-6 play a pivotal role in the pathological processes of RA, biologics targeting these cytokines with MTX, have revolutionized the treatment of RA, producing significant improvement in clinical, radiographic and functional outcomes not seen previously. However, even with these drugs the frequency and degree of responses are restricted. Therefore, new agents targeting cell surface molecules which are involved in cellular interaction and/or signaling on immune cells have been emerging, in order to increase response rates and to achieve high frequencies of remission or even cure. Two biologics abatacept, a CTLA4-Ig fusion protein, and rituximab, an anti-CD20 antibody, were launched in US and EU for the treatment of RA and many biologics are under the clinical trials from the similar concept. Thus, certain biologics have brought about paradigm shift in the treatment of rheumatic diseases, but an economical issue remains unsolved. In order to overcome the concern, low molecular weight chemical products have been rethought. Not a few agents targeting intracellular activation signaling in immune cells such as Jak and Syk are under clinical examinations and some of them appear to show wonderful results, which are comparable to biologics in the context of the treatment of rheumatic diseases. The prospects are here." @default.
- W284128977 created "2016-06-24" @default.
- W284128977 creator A5015953107 @default.
- W284128977 date "2009-03-01" @default.
- W284128977 modified "2023-09-24" @default.
- W284128977 title "Recent progress in clinical trials for rheumatic diseases" @default.
- W284128977 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19280942" @default.
- W284128977 hasPublicationYear "2009" @default.
- W284128977 type Work @default.
- W284128977 sameAs 284128977 @default.
- W284128977 citedByCount "0" @default.
- W284128977 crossrefType "journal-article" @default.
- W284128977 hasAuthorship W284128977A5015953107 @default.
- W284128977 hasConcept C126322002 @default.
- W284128977 hasConcept C151730666 @default.
- W284128977 hasConcept C159654299 @default.
- W284128977 hasConcept C203014093 @default.
- W284128977 hasConcept C2777178219 @default.
- W284128977 hasConcept C2777575956 @default.
- W284128977 hasConcept C2778886723 @default.
- W284128977 hasConcept C2779134260 @default.
- W284128977 hasConcept C2779343474 @default.
- W284128977 hasConcept C2779605438 @default.
- W284128977 hasConcept C2780653079 @default.
- W284128977 hasConcept C2781059491 @default.
- W284128977 hasConcept C535046627 @default.
- W284128977 hasConcept C59491497 @default.
- W284128977 hasConcept C71924100 @default.
- W284128977 hasConcept C86803240 @default.
- W284128977 hasConcept C8891405 @default.
- W284128977 hasConceptScore W284128977C126322002 @default.
- W284128977 hasConceptScore W284128977C151730666 @default.
- W284128977 hasConceptScore W284128977C159654299 @default.
- W284128977 hasConceptScore W284128977C203014093 @default.
- W284128977 hasConceptScore W284128977C2777178219 @default.
- W284128977 hasConceptScore W284128977C2777575956 @default.
- W284128977 hasConceptScore W284128977C2778886723 @default.
- W284128977 hasConceptScore W284128977C2779134260 @default.
- W284128977 hasConceptScore W284128977C2779343474 @default.
- W284128977 hasConceptScore W284128977C2779605438 @default.
- W284128977 hasConceptScore W284128977C2780653079 @default.
- W284128977 hasConceptScore W284128977C2781059491 @default.
- W284128977 hasConceptScore W284128977C535046627 @default.
- W284128977 hasConceptScore W284128977C59491497 @default.
- W284128977 hasConceptScore W284128977C71924100 @default.
- W284128977 hasConceptScore W284128977C86803240 @default.
- W284128977 hasConceptScore W284128977C8891405 @default.
- W284128977 hasIssue "3" @default.
- W284128977 hasLocation W2841289771 @default.
- W284128977 hasLocation W2841289772 @default.
- W284128977 hasOpenAccess W284128977 @default.
- W284128977 hasPrimaryLocation W2841289771 @default.
- W284128977 hasRelatedWork W126335135 @default.
- W284128977 hasRelatedWork W160475951 @default.
- W284128977 hasRelatedWork W1870753475 @default.
- W284128977 hasRelatedWork W2014398501 @default.
- W284128977 hasRelatedWork W2071045939 @default.
- W284128977 hasRelatedWork W2099290017 @default.
- W284128977 hasRelatedWork W2107255073 @default.
- W284128977 hasRelatedWork W2113277495 @default.
- W284128977 hasRelatedWork W2116266891 @default.
- W284128977 hasRelatedWork W2123402838 @default.
- W284128977 hasRelatedWork W2131657597 @default.
- W284128977 hasRelatedWork W2137748785 @default.
- W284128977 hasRelatedWork W2143478147 @default.
- W284128977 hasRelatedWork W2156702151 @default.
- W284128977 hasRelatedWork W2338072947 @default.
- W284128977 hasRelatedWork W2471210286 @default.
- W284128977 hasRelatedWork W2785384817 @default.
- W284128977 hasRelatedWork W2989167577 @default.
- W284128977 hasRelatedWork W2153534970 @default.
- W284128977 hasRelatedWork W2342412350 @default.
- W284128977 hasVolume "67" @default.
- W284128977 isParatext "false" @default.
- W284128977 isRetracted "false" @default.
- W284128977 magId "284128977" @default.
- W284128977 workType "article" @default.